Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.

Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM.

J Thorac Oncol. 2019 Aug 22. pii: S1556-0864(19)30665-3. doi: 10.1016/j.jtho.2019.08.003. [Epub ahead of print]

PMID:
31446141
2.

A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer.

Chen EY, Blanke CD, Haller DG, Benson AB, Dragovich T, Lenz HJ, Robles C, Li H, Mori M, Mattek N, Sanborn RE, Lopez CD.

Am J Clin Oncol. 2018 Dec;41(12):1193-1198. doi: 10.1097/COC.0000000000000465.

PMID:
29782360
3.

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.

Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR.

Ann Oncol. 2018 Jul 1;29(7):1548-1553. doi: 10.1093/annonc/mdy177.

PMID:
29767677
4.

A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.

Giaccone G, Sanborn RE, Waqar SN, Martinez-Marti A, Ponce S, Zhen H, Kennealey G, Erickson-Viitanen S, Schaefer E.

Clin Lung Cancer. 2018 Sep;19(5):e567-e574. doi: 10.1016/j.cllc.2018.03.016. Epub 2018 Mar 23.

PMID:
29681434
5.

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.

Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA.

Clin Cancer Res. 2018 Jun 15;24(12):2771-2779. doi: 10.1158/1078-0432.CCR-17-2398. Epub 2018 Mar 21.

6.

A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.

Sanborn RE, Ross HJ, Aung S, Acheson A, Moudgil T, Puri S, Hilton T, Fisher B, Coffey T, Paustian C, Neuberger M, Walker E, Hu HM, Urba WJ, Fox BA.

J Immunother Cancer. 2017 Dec 19;5(1):103. doi: 10.1186/s40425-017-0306-6.

7.

Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).

Arnold SM, Chansky K, Leggas M, Thompson MA, Villano JL, Hamm J, Sanborn RE, Weiss GJ, Chatta G, Baggstrom MQ.

Invest New Drugs. 2017 Oct;35(5):608-615. doi: 10.1007/s10637-017-0441-4. Epub 2017 Feb 16.

8.

A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.

Sanborn RE, Patel JD, Masters GA, Jayaram N, Stephens A, Guarino M, Misleh J, Wu J, Hanna N.

Cancer. 2017 Jan 1;123(2):303-311. doi: 10.1002/cncr.30287. Epub 2016 Sep 1.

9.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH.

J Clin Oncol. 2016 Sep 10;34(26):3119-25. doi: 10.1200/JCO.2016.67.9761. Epub 2016 Jun 6.

10.

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.

Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ, Rizvi NA.

Lancet Oncol. 2016 Mar;17(3):299-308. doi: 10.1016/S1470-2045(15)00544-6. Epub 2016 Feb 6.

11.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS.

Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20.

12.

Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.

Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, Evans TL, Schneider BJ, Keresztes R, Rogers JS, de Mayolo JA, Feliciano J, Yang Y, Medeiros M, Zaknoen SL.

J Clin Oncol. 2015 Jan 10;33(2):189-94. doi: 10.1200/JCO.2014.55.5789. Epub 2014 Dec 1.

13.

Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.

Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, Kluger H, Tejwani S, Green J, Ramakrishna V, Crocker A, Vitale L, Yellin M, Davis T, Keler T.

Sci Transl Med. 2014 Apr 16;6(232):232ra51. doi: 10.1126/scitranslmed.3008068.

14.

OX40 is a potent immune-stimulating target in late-stage cancer patients.

Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L, Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD.

Cancer Res. 2013 Dec 15;73(24):7189-7198. doi: 10.1158/0008-5472.CAN-12-4174. Epub 2013 Oct 31.

15.

Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma.

Lau DH, Moon J, Davies AM, Sanborn RE, Hirsch FR, Franklin WA, Ruzich JC, Redman MW, Gandara DR.

Clin Lung Cancer. 2013 Jul;14(4):351-5. doi: 10.1016/j.cllc.2012.12.004. Epub 2013 Feb 14.

16.

A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.

Clément-Duchêne C, Natale RB, Jahan T, Krupitskaya Y, Osarogiagbon R, Sanborn RE, Bernstein ED, Dudek AZ, Latz JE, Shi P, Wakelee HA.

Lung Cancer. 2012 Oct;78(1):57-62. doi: 10.1016/j.lungcan.2012.06.003. Epub 2012 Jul 17.

17.

Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.

Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, Cormier Y, Stephenson J, Ung Y, Sanborn R, Pressnail B, Nugent F, Nemunaitis J, Gleave ME, Murray N, Hao D.

J Thorac Oncol. 2012 Mar;7(3):579-86. doi: 10.1097/JTO.0b013e31823f459c.

18.

Cisplatin versus carboplatin in NSCLC: is there one "best" answer?

Sanborn RE.

Curr Treat Options Oncol. 2008 Dec;9(4-6):326-42. doi: 10.1007/s11864-009-0085-5. Epub 2009 Feb 19. Review.

PMID:
19225891
19.

Erlotinib: applications in therapy and current status of research.

Sanborn RE, Davies AM.

Expert Rev Clin Pharmacol. 2009 Jan;2(1):15-36. doi: 10.1586/17512433.2.1.15.

PMID:
24422769
20.

Adjuvant therapy for non-small cell lung cancer with mediastinal nodal involvement.

Sanborn RE, Lally BE.

Thorac Surg Clin. 2008 Nov;18(4):423-35. doi: 10.1016/j.thorsurg.2008.08.004. Review.

PMID:
19086611
21.

Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.

Tieu BH, Sanborn RE, Thomas CR Jr.

Thorac Surg Clin. 2008 Nov;18(4):403-15. doi: 10.1016/j.thorsurg.2008.07.004. Review.

PMID:
19086609
22.

Definitive chemoradiotherapy for non-small cell lung cancer with N2 disease.

Patel S, Sanborn RE, Thomas CR Jr.

Thorac Surg Clin. 2008 Nov;18(4):393-401. doi: 10.1016/j.thorsurg.2008.07.003. Review.

PMID:
19086608
23.

Cutaneous reactions to chemotherapy: commonly seen, less described, little understood.

Sanborn RE, Sauer DA.

Dermatol Clin. 2008 Jan;26(1):103-19, ix. Review.

PMID:
18023774
24.

The safety of bevacizumab.

Sanborn RE, Sandler AB.

Expert Opin Drug Saf. 2006 Mar;5(2):289-301. Review.

PMID:
16503749
25.

Gastrointestinal stromal tumors and the evolution of targeted therapy.

Sanborn RE, Blanke CD.

Clin Adv Hematol Oncol. 2005 Aug;3(8):647-57. Review.

PMID:
16167051
26.

Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?

Sanborn R, Blanke CD.

Semin Oncol. 2005 Feb;32(1):69-75. Review.

PMID:
15726508
27.

Gender differences in autobiographical memory styles of older adults.

Pillemer DB, Wink P, DiDonato TE, Sanborn RL.

Memory. 2003 Nov;11(6):525-32.

PMID:
14982120
28.

Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.

Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D, Wickrema A, Yassine M, Amin K, Thomason D, Chen YH, Devine H, Maningo M, van Besien K.

Bone Marrow Transplant. 2001 Sep;28(6):557-62.

29.

Intraoperative epidural catheter malfunction in two obese patients.

Leith P, Sanborn R, Brock-Utne JG.

Acta Anaesthesiol Scand. 1997 May;41(5):651-3.

PMID:
9181171
30.
31.

Cardioregulation in limulus. II. Gamma aminobutyric acid, antagonists and inhibitor nerves.

Pax RA, Sanborn RC.

Biol Bull. 1967 Jun;132(3):381-91. No abstract available.

PMID:
6046027
32.

Observations on the susceptibility of some insect to Nosema (Microsporidia: Sporozoa).

FISHER FM Jr, SANBORN RC.

J Parasitol. 1962 Dec;48:926-32. No abstract available.

PMID:
13945275
33.

Production of insect juvenile hormone by the microsporidian parasite Nosema.

FISHER FM Jr, SANBORN RC.

Nature. 1962 Jun 23;194:1193. No abstract available.

PMID:
13893240
34.

The effect of temperature on oxidative phosphorylation with insect flight muscle mitochondria.

SACKTOR B, SANBORN R.

J Biophys Biochem Cytol. 1956 Jan 25;2(1):105-7.

35.
36.

The cytochrome system in relation to diapause and development in Cecropia silkworm.

WILLIAMS CM, SANBORN RC.

Biol Bull. 1948 Oct;95(2):282. No abstract available.

PMID:
18933459
37.

What sanitation means to the processor.

SANBORN RE.

Food Ind. 1946 Jan;18:94-6. No abstract available.

PMID:
21009698

Supplemental Content

Loading ...
Support Center